secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2022-06-30T23:59:59+00:00
Accession:  0001564590-22-024914
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly to supply additional 150K doses of AbCellera's bebtelovimab for ~$275M
----------------------------------------------------------------------------

- Eli Lilly modified agreement with U.S. government for 150,000 additional doses of bebtelovimab at ~$275M.
- Delivery begins immediately and completes by August 5, 2022; option for 350,000 more doses by Sep 14, 2022.
- Bebtelovimab maintains neutralization against Omicron variants BA.2.12.1 and BA.4/BA.5, plus all known variants.
- Existing supply plus new purchase expected to meet U.S. demand through late August 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000156459022024914/0001564590-22-024914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000156459022024914/abcl-8k_20220629.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-024914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer